The efficacy of Ursudoxicolic acid combination with fenofibrate in patients with primary sclerosing cholangitis

Not Applicable

Recruiting

• Conditions: primary scleroding cholangitis.; K80-K87; 80.5

• Registration Number: IRCT20080901001155N31
• Lead Sponsor: Rasht University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 August 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Patients with PSC disease confirmed by a specialist using ERCP or MRCP.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Primary scleroding cholangitis treatment. Timepoint: Before starting treatment, weeks 6, 12,18,24,30,36 from the point of view ALT, AST, ALP, Gamma- Glutamyl transpeptidase, Bilirubin Total, Bilirubin Direct,Albumin and Prothrombin and weeks 12,24,36 from the point of view TG, Total-Cholesetrol and LDL. Method of measurement: Blood test.

Secondary Outcome Measures

Name	Time	Method
Response to treatment and possible side effect. Timepoint: Weeks 6, 12,18,24,30,36 from the point of view ALT, AST, ALP,Gamma-Glutamyl transpeptidase,Bilirubin Total,Bilirubin Direct,Albumin and Protrombin and weeks 12,24,36 from the point of view TG, Total-Cholestrol and LDL. Method of measurement: Blood test.